The RTS, S malaria vaccine: Current impact and foundation for the future

JG Beeson, L Kurtovic, C Valim, KP Asante… - Science Translational …, 2022 - science.org
The RTS, S vaccine has recently been recommended for implementation as a childhood
vaccine in regions with moderate-to-high malaria transmission. We discuss mechanisms of …

Malaria vaccines: progress to date

DI Stanisic, MF Good - BioDrugs, 2023 - Springer
Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Malaria vaccines: from the past towards the mRNA vaccine era

ME Tsoumani, C Voyiatzaki, A Efstathiou - Vaccines, 2023 - mdpi.com
Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease
transmitted by infected mosquitoes. Malaria remains a major global health challenge …

Malaria vaccines: a new era of prevention and control

PE Duffy, JP Gorres, SA Healy, M Fried - Nature Reviews Microbiology, 2024 - nature.com
Malaria killed over 600,000 people in 2022, a death toll that has not improved since 2015.
Additionally, parasites and mosquitoes resistant to existing interventions are spreading …

A critical review on human malaria and schistosomiasis vaccines: current state, recent advancements, and developments

AJ Siddiqui, J Bhardwaj, J Saxena, S Jahan, M Snoussi… - Vaccines, 2023 - mdpi.com
Malaria and schistosomiasis are two major parasitic diseases that remain leading causes of
morbidity and mortality worldwide. Co-infections of these two parasites are common in the …

Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies

M Chutiyami, P Saravanakumar, UM Bello, D Salihu… - Infection, 2024 - Springer
Aim The review summarizes the recent empirical evidence on the efficacy, safety, and
community perception of malaria vaccines in Africa. Methods Academic Search Complete …

Vaccines and monoclonal antibodies: new tools for malaria control

K Miura, Y Flores-Garcia, CA Long… - Clinical Microbiology …, 2024 - Am Soc Microbiol
Malaria remains one of the biggest health problems in the world. While significant reductions
in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend …

Protective antibody threshold of RTS, S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model

CJ Genito, K Brooks, A Smith, E Ryan, K Soto, Y Li… - npj Vaccines, 2023 - nature.com
Mouse models are useful for the early down-selection of malaria vaccine candidates. The
Walter Reed Army Institute of Research has optimized a transgenic Plasmodium berghei …

Blood-stage malaria vaccine candidate RH5. 1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre …

SE Silk, WF Kalinga, J Salkeld, IM Mtaka… - The Lancet Infectious …, 2024 - thelancet.com
Background A blood-stage Plasmodium falciparum malaria vaccine would provide a second
line of defence to complement partially effective or waning immunity conferred by the …

Genotypic analysis of RTS, S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in …

M Juraska, AM Early, L Li, SF Schaffner… - The Lancet Infectious …, 2024 - thelancet.com
Background The first licensed malaria vaccine, RTS, S/AS01 E, confers moderate protection
against symptomatic disease. Because many malaria infections are asymptomatic, we …